644 related articles for article (PubMed ID: 35936003)
21. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
22. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
[TBL] [Abstract][Full Text] [Related]
23. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
24. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
Date V; Nair S
Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
[TBL] [Abstract][Full Text] [Related]
25. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
26. RNA Therapeutics for Improving CAR T-cell Safety and Efficacy.
Schaible P; Bethge W; Lengerke C; Haraszti RA
Cancer Res; 2023 Feb; 83(3):354-362. PubMed ID: 36512627
[TBL] [Abstract][Full Text] [Related]
27. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
28. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
29. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
[TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
31. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
32. Metabolic challenges and interventions in CAR T cell therapy.
Peng JJ; Wang L; Li Z; Ku CL; Ho PC
Sci Immunol; 2023 Apr; 8(82):eabq3016. PubMed ID: 37058548
[TBL] [Abstract][Full Text] [Related]
33. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
34. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
Roselli E; Faramand R; Davila ML
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
[TBL] [Abstract][Full Text] [Related]
35. Engineering Next-Generation CAR-T Cells for Better Toxicity Management.
Andrea AE; Chiron A; Bessoles S; Hacein-Bey-Abina S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207607
[TBL] [Abstract][Full Text] [Related]
36. Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey SR; Vatsa S; Larson RC; Bouffard AA; Scarfò I; Kann MC; Berger TR; Leick MB; Wehrli M; Schmidts A; Silva H; Lindell KA; Demato A; Gallagher KME; Frigault MJ; Maus MV
Blood Cancer Discov; 2022 Mar; 3(2):136-153. PubMed ID: 35015685
[TBL] [Abstract][Full Text] [Related]
37. Current Progress in CAR-T Cell Therapy for Solid Tumors.
Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
39. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
Dabas P; Danda A
Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
[TBL] [Abstract][Full Text] [Related]
40. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]